Escitalopram

07/01/2014 - "We investigated which factors can best predict relapse in older patients with major depressive disorder (MDD) who have achieved remission with escitalopram. "
03/01/2007 - "This prospective economic analysis demonstrated that escitalopram is a cost-effective first-line treatment option for major depressive disorder."
03/01/2005 - "Escitalopram is an effective, well-tolerated treatment for major depressive disorder in both primary and specialist settings. "
01/01/2004 - "Continuation treatment with escitalopram is effective in preventing relapse into an episode of major depressive disorder."
06/01/2004 - "Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria."

08/01/2005 - "Three randomized controlled trials recently evaluated the safety and efficacy of escitalopram in the treatment of generalized anxiety disorder (GAD). "
09/01/2006 - "To assess the efficacy of different doses of escitalopram in generalised anxiety disorder. "
11/01/2005 - "Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder."
09/02/2023 - "We examined gastrointestinal symptoms in youth with anxiety disorders during a double-blind, placebo-controlled trial of escitalopram (n = 51). "
06/01/2023 - "Correction to: A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder, by Strawn et al. J Child Adolesc Psychopharmacol 2023;33(3):91-100; doi: 10.1089/cap.2023.0004."

10/01/2005 - "Escitalopram has proven efficacy in the short-term treatment of generalized social anxiety disorder (SAD). "
01/01/2016 - "In this first 52-week clinical study of social anxiety disorder, escitalopram 10-20 mg/day was safe, well tolerated, and effective in Japanese patients."
05/31/2016 - "Early Improvement in One Week Predicts the Treatment Response to Escitalopram in Patients with Social Anxiety Disorder: A Preliminary Study."
01/01/2016 - "Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo."
01/01/2004 - "Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions."

09/01/2013 - "Escitalopram or PST was significantly more effective in preventing new onset of apathy following stroke compared with placebo."
01/01/2014 - "Although these results should be considered preliminary, the authors found that both escitalopram and PST were effective in preventing new onset of post-stroke GAD. "
11/01/2021 - "This is a post hoc analysis of EMOTION (ClinicalTrials.gov, NCT01278498), a randomized, placebo-controlled, double-blind trial that examined the efficacy of escitalopram on depression in acute stroke patients (237 with placebo, 241 with escitalopram). "
05/01/2021 - "This is a sub-study of EMOTION, a randomized, placebo-controlled trial, that examined the efficacy of escitalopram on PSD, PSEI, and PSA in patients with stroke. "
01/01/2020 - "This is a post hoc analysis of EMOTION (ClinicalTrials.gov, NCT01278498), a randomized, placebo-controlled, double-blind trial that examined the efficacy of escitalopram for 3 months on depression in patients with acute stroke. "

11/01/2003 - "The frequency of panic attacks was statistically significantly improved (p =.04), and the increase in percentage of patients with zero panic attacks reached borderline significance (p =.051), in the escitalopram-treated group relative to the placebo-treated group. "
09/01/2008 - "On the whole, numerous clinical data indicate that escitalopram, 10-20 mg/d, is an effective and well-tolerated first-line treatment option for the management of panic disorder, GAD, social anxiety and OCD. "
01/01/2006 - "Nevertheless, available clinical data indicate that escitalopram is an effective first-line treatment option for the management of GAD, SAD, panic disorder and OCD."
11/01/2003 - "This study evaluated the safety and efficacy of escitalopram in outpatients diagnosed with panic disorder. "
05/30/2012 - "We aimed to examine whether anxiety sensitivity and agoraphobic fear could affect the time taken to remission after 24 weeks of open-label escitalopram treatment of patients with panic disorder (PD). "